BR112017005993A2 - derivados de peptídeo inovadores e usos dos mesmos - Google Patents

derivados de peptídeo inovadores e usos dos mesmos

Info

Publication number
BR112017005993A2
BR112017005993A2 BR112017005993A BR112017005993A BR112017005993A2 BR 112017005993 A2 BR112017005993 A2 BR 112017005993A2 BR 112017005993 A BR112017005993 A BR 112017005993A BR 112017005993 A BR112017005993 A BR 112017005993A BR 112017005993 A2 BR112017005993 A2 BR 112017005993A2
Authority
BR
Brazil
Prior art keywords
peptide derivatives
innovative
innovative peptide
compositions
novel peptide
Prior art date
Application number
BR112017005993A
Other languages
English (en)
Inventor
RACINE Emilie
Gualtieri Maxime
VILLAIN-GUILLOT Philippe
Original Assignee
Nosopharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nosopharm filed Critical Nosopharm
Publication of BR112017005993A2 publication Critical patent/BR112017005993A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

a presente invenção fornece derivados de peptídeo inovadores e composições que compreendem os mesmos. a invenção fornece adicionalmente métodos de tratamento que compreendem administrar derivados de peptídeo inovadores e/ou composições que compreendem os mesmos.
BR112017005993A 2014-09-26 2015-09-25 derivados de peptídeo inovadores e usos dos mesmos BR112017005993A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306504 2014-09-26
PCT/EP2015/072185 WO2016046409A1 (en) 2014-09-26 2015-09-25 Novel peptide derivatives and uses thereof

Publications (1)

Publication Number Publication Date
BR112017005993A2 true BR112017005993A2 (pt) 2017-12-19

Family

ID=51663118

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017005993A BR112017005993A2 (pt) 2014-09-26 2015-09-25 derivados de peptídeo inovadores e usos dos mesmos

Country Status (13)

Country Link
US (1) US10626144B2 (pt)
EP (1) EP3197908A1 (pt)
JP (2) JP7123559B2 (pt)
KR (1) KR102522224B1 (pt)
CN (1) CN106715460B (pt)
AU (1) AU2015323713B2 (pt)
BR (1) BR112017005993A2 (pt)
CA (1) CA2961297A1 (pt)
IL (1) IL251289B (pt)
MA (1) MA40642A (pt)
MX (1) MX2017003949A (pt)
RU (1) RU2699572C2 (pt)
WO (1) WO2016046409A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017005993A2 (pt) * 2014-09-26 2017-12-19 Nosopharm derivados de peptídeo inovadores e usos dos mesmos
CN113185549A (zh) * 2021-04-30 2021-07-30 河北农业大学 一种Wittig-Horner试剂的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1451623A (fr) 1964-09-29 1966-01-07 Associated Semiconductor Mft Procédé d'application d'une couche de bioxyde de germanium tétragonal sur un corps de germanium
WO2001021189A1 (en) * 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
US20090325312A1 (en) * 2006-05-12 2009-12-31 Ailan Guo Reagens for the detection of protein acetylation signaling pathways
WO2009106073A2 (en) 2008-02-28 2009-09-03 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
US9260481B2 (en) * 2011-09-28 2016-02-16 Nosopharm Peptide derivatives as antibiotics
US9745581B2 (en) * 2012-05-16 2017-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of treating and diagnosing diseases using agents that regulate the alternative splicing pathway
BR112017005993A2 (pt) 2014-09-26 2017-12-19 Nosopharm derivados de peptídeo inovadores e usos dos mesmos

Also Published As

Publication number Publication date
EP3197908A1 (en) 2017-08-02
IL251289B (en) 2021-02-28
RU2017112510A3 (pt) 2019-02-25
US10626144B2 (en) 2020-04-21
JP7123559B2 (ja) 2022-08-23
WO2016046409A1 (en) 2016-03-31
US20170298097A1 (en) 2017-10-19
JP2021100939A (ja) 2021-07-08
RU2017112510A (ru) 2018-11-01
MX2017003949A (es) 2018-01-12
CN106715460A (zh) 2017-05-24
AU2015323713A1 (en) 2017-04-20
JP2017533890A (ja) 2017-11-16
IL251289A0 (en) 2017-05-29
KR20170057400A (ko) 2017-05-24
RU2699572C2 (ru) 2019-09-06
MA40642A (fr) 2016-03-31
CA2961297A1 (en) 2016-03-31
AU2015323713B2 (en) 2020-04-23
CN106715460B (zh) 2022-04-08
KR102522224B1 (ko) 2023-04-14

Similar Documents

Publication Publication Date Title
BR112017020149A2 (pt) derivados de maitansinoide, conjugados dos mesmos e métodos de uso
PH12016502468A1 (en) Influenza virus vaccines and uses thereof
BR112018012164A2 (pt) anticorpos neutralizantes do vírus da imunodeficiência humana
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112017015614A2 (pt) produtos terapêuticos de glicano e métodos relacionados dos mesmos.
EA201691582A1 (ru) Новые фармацевтические препараты
BR112016028891A2 (pt) processos de trens de sementes e usos dos mesmos
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
BR112016022062A2 (pt) Combinação, composição farmacêutica, uso de uma combinação ou de uma composição farmacêutica, e, produto farmacêutico
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
PH12016502500A1 (en) Influenza virus vaccines and uses thereof
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
BR112017008714A2 (pt) inibidores de bromodomínio
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
BR112016016274A2 (pt) Ponte da barreira hematoencefálica
BR112017007414A2 (pt) combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla
BR112018002382A8 (pt) Novos anticorpos anti-gvpi humano e usos dos mesmos
DOP2017000260A (es) Piroglutamato de vortioxetina
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]